Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Shayan DiounLing ChenAlexander MelamedAllison GockleyCaryn M St ClairJune Y HouFady Khoury-ColladoChin HurElena ElkinMelissa AccordinoDawn L HershmanJason D WrightPublished in: BJOG : an international journal of obstetrics and gynaecology (2022)
Dostarlimab is associated with greater survival compared with other treatments for women with recurrent dMMR endometrial cancer. Although the agent is substantially more costly, dostarlimab became cost-effective when its cost was reduced to $5489 per cycle.
Keyphrases